Zacks Investment Research downgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “

Several other brokerages also recently weighed in on NBRV. BidaskClub downgraded Zebra Technologies from a hold rating to a sell rating in a research report on Friday, May 24th. HC Wainwright boosted their price objective on Palatin Technologies from $5.00 to $6.00 and gave the company a buy rating in a research report on Thursday, May 9th. Gabelli reiterated a buy rating on shares of Flushing Financial in a research report on Thursday, May 2nd. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Finally, Needham & Company LLC restated a buy rating and set a $10.00 target price (down previously from $15.00) on shares of Nabriva Therapeutics in a report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $7.34.

Shares of NBRV stock opened at $2.44 on Wednesday. The company has a quick ratio of 5.55, a current ratio of 5.55 and a debt-to-equity ratio of 0.40. Nabriva Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $3.58. The company has a 50 day moving average of $2.25.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.56 million. On average, equities analysts predict that Nabriva Therapeutics will post -1.14 EPS for the current year.

Several institutional investors have recently made changes to their positions in NBRV. FMR LLC raised its holdings in shares of Nabriva Therapeutics by 514.2% during the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after acquiring an additional 1,542,700 shares in the last quarter. Fosun International Ltd purchased a new stake in Nabriva Therapeutics in the first quarter worth $1,593,000. Paloma Partners Management Co purchased a new stake in Nabriva Therapeutics in the fourth quarter worth $54,000. Two Sigma Advisers LP purchased a new stake in Nabriva Therapeutics in the fourth quarter worth $37,000. Finally, HRT Financial LLC purchased a new stake in Nabriva Therapeutics in the fourth quarter worth $31,000. Institutional investors own 3.02% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.